Letteratura Scientifica

Monoclonal antibodies that target amyloid-beta (Aβ) have the potential to slow cognitive and functional decline in persons with early Alzheimer’s disease. Gantenerumab is a subcutaneously administered, fully human, anti-Aβ IgG1 monoclonal antibody with highest affinity for aggregated Aβ that has been tested for the treatment of Alzheimer’s disease.

Konstantinos Prokopidis 1, Masoud Isanejad 1, Asangaedem Akpan 1 2, Maria Stefil 3 4, Behnam Tajik 5 6, Panagiotis Giannos 7, Massimo Venturelli 4, Rajiv Sankaranarayanan 3 8

Ruzhao Chen MS1,2 | Jiachen Xu MS2 | Yuge Wang MS2 | Benyue Jiang MS2 |
Xiao Xu MS2 | Yang Lan MS2 | Jiang Wang MD2 | Xiufang Lin MD1

Artur Fedorowski, MD, PhD1,2, Fabrizio Ricci, MD, PhD, Msc1,3,4, Viktor Hamrefors, MD, PhD1,5, Kristin E. Sandau, PhD6, Tae Hwan Chung, MD7, James A. S. Muldowney, MD8, Rakesh Gopinathannair, MD, MA9, Brian Olshansky, MD10

Henriette Hummler 1,2 , Cordula Stillhart 1 , Lisa Meilicke 2, Michael Grimm 2 , Elischa Krause 3 ,
Marwan Mannaa 4, Maik Gollasch 4, WernerWeitschies 2 and Susanne Page 1,*

Beatrice Arosio 1 , Riccardo Calvani 2,3 , Evelyn Ferri 4, Hélio José Coelho-Junior 3 , Angelica Carandina 1 ,
Federica Campanelli 5, Veronica Ghiglieri 2,6 , Emanuele Marzetti 2,3,* and Anna Picca 2,7

Szu-Yun Wu 1 , Yu-Yao Cheng 2, Hsing-Yi Chang 3 , Pei-Hsuan Wang 1, I-Ching Hsieh 1, Nai-Hua Yeh 1,
Kuo-Chin Huang 4 and Wen-Harn Pan 1,3,5,*

Caterina Trevisan1,2,3*†, Marianna Noale4†, Giancarlo Zatti1, Davide Liborio Vetrano3,5, Stefania Maggi4 and Giuseppe Sergi1